A Phase II of Rituximab in Myasthenia Gravis (NN 103)

Grant

Date/time Interval

  • April 21, 2014 - August 31, 2018
  • Total Award Amount

  • 16536.00
  • Direct Costs

  • 11249.00
  • Sponsor Award Id

  • Contributor

  • Eroboghene Ubogu   Investigator